Allarity Therapeutics, Inc. income statement

In fiscal 2025, Allarity Therapeutics, Inc. reported revenue of $320,000, operating income of −$12.6m (a -3939.1% margin) and net income of −$11.2m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Allarity Therapeutics, Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025
Revenue	0	0
Research and development	6	7
General and administrative	11	6
Operating income	−27	−13
Interest expense	1	0
Income before tax	−25	−11
Income tax	−0	0
Net income	−25	−11
Diluted shares (average)	2m	14m
EBITDA	−27	—

US$ thousands unless shown otherwise. Fiscal quarters.

Allarity Therapeutics, Inc.: income statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	25	0
Research and development	1,403	2,321	1,297	1,345
General and administrative	1,633	1,812	1,416	1,326
Operating income	−3,036	−4,133	−2,688	−2,671
Interest expense	57	12	229	719
Income before tax	−2,732	−2,320	—	—
Income tax	0	0	—	—
Net income	−2,732	−2,320	−2,750	−3,405
EBITDA	−3,025	−4,121	—	—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Allarity Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Allarity Therapeutics, Inc.